Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3039478 QT/QTc and Bioavailability Study
NCT02659865Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crenigacestat in solid tumor (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean Time-Matched Difference in Placebo-Adjusted QTcF Interval at 48 hours. Started Jan 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02659865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659865.